IP Library › Granted Patent US 12,599,665
Granted Patent B2
US 12,599,665 · App. 18/020,728 · Granted Apr 14, 2026

Gene fusions for control of genetically modified cells

Inventors: Jee Young Mock (North Hollywood, CA); Carl Alexander Kamb (Thousand Oaks, CA); Agnes Hamburger (Newbury Park, CA)
Assignee: A2 Biotherapeutics, Inc.
A61K40/11A61K31/138A61K40/22A61K40/30A61K40/31A61K40/412C07K14/4747C07K14/7051C07K14/721C12N5/0636C12N15/86A61K2239/25C07K2319/00C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,665
App. No.
18/020,728
Granted
Apr 14, 2026
Kind
B2
Abstract

The disclosure relates to fusion proteins comprising a tBID polypeptide and a steroid hormone receptor domain, and methods of using same to induce apoptosis in cells.

Claims (14)

1 . A polynucleotide comprising a polynucleotide sequence encoding a fusion protein, the fusion protein comprising a truncated BH3-interacting domain death agonist (tBID) polypeptide and a steroid hormone receptor (SHR) domain polypeptide, wherein the tBID polypeptide comprises a deletion of BID helix 1 and BID helix 2,

and wherein any of A-D is true:

a) wherein the tBID polypeptide shares at least 95% identity to SEQ ID NO: 1;

b) wherein the tBID polypeptide shares at least 95% identity to SEQ ID NO: 93;

c) wherein the fusion protein shares at least 95% identity to ESR1-D (SEQ ID NO: 4);

d) wherein the fusion protein shares at least 95% identity to D-ESR1 (SEQ ID NO: 5);

e) wherein the fusion protein shares at least 95% identity to ESR1-C(SEQ ID NO: 6);

f) wherein the fusion protein shares at least 95% identity to C-ESR1 (SEQ ID NO: 7); or

g) wherein the fusion protein shares at least 95% identity to H-ESR1 (SEQ ID NO: 97).

2 . A vector comprising the polynucleotide of claim 1 .

3 . The vector of claim 2 , wherein the vector is a lentiviral vector.

4 . An isolated immune cell comprising the polynucleotide of claim 1 .

5 . A method of controlling proliferation of transplanted immune cells in a subject previously transplanted with the immune cell of claim 4 , comprising administering a hormone that specifically binds the SHR domain polypeptide of the fusion protein.

6 . A method of making an immune cell, comprising introducing the polynucleotide of claim 1 into an immune cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023
From: MOCK, JEE YOUNG; KAMB, CARL ALEXANDER; HAMBURGER, AGNES
To: A2 BIOTHERAPEUTICS, INC.
Reel/Frame 063595/0125 →
Continuity (2)
Provisional Application 63065321 · Aug 13, 2020
Related Publication 20230330227A1 · Oct 19, 2023
References Cited (87)
US 5192525A · Yang et al. · 1993 [cited by applicant]
US 5350674A · Boenisch et al. · 1994 [cited by applicant]
US 5585362A · Wilson et al. · 1996 [cited by applicant]
US 5858358A · June et al. · 1999 [cited by applicant]
US 5883223A · Gray · 1999 [cited by applicant]
US 5994136A · Naldini et al. · 1999 [cited by applicant]
US 5998583A · Korsmeyer · 1999 [cited by examiner]
US 6013516A · Verma et al. · 2000 [cited by applicant]
US 6326193B1 · Liu et al. · 2001 [cited by applicant]
US 6352694B1 · June et al. · 2002 [cited by applicant]
US 6534055B1 · June et al. · 2003 [cited by applicant]
US 6692964B1 · June et al. · 2004 [cited by applicant]
US 6797514B2 · Berenson et al. · 2004 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6887466B2 · June et al. · 2005 [cited by applicant]
US 6905680B2 · June et al. · 2005 [cited by applicant]
US 6905681B1 · June et al. · 2005 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7067318B2 · June et al. · 2006 [cited by applicant]
US 7144575B2 · June et al. · 2006 [cited by applicant]
US 7172869B2 · June et al. · 2007 [cited by applicant]
US 7175843B2 · June et al. · 2007 [cited by applicant]
US 7232566B2 · June et al. · 2007 [cited by applicant]
US 8530168B2 · Chu et al. · 2013 [cited by applicant]
US 10040846B2 · Frigault et al. · 2018 [cited by applicant]
US 20030109683A1 · Omalley et al. · 2003 [cited by applicant]
US 20040101519A1 · June et al. · 2004 [cited by applicant]
US 20060034810A1 · Riley et al. · 2006 [cited by applicant]
US 20060121005A1 · Berenson et al. · 2006 [cited by applicant]
US 20110023137A1 · Chu et al. · 2011 [cited by applicant]
US 20190008797A1 · Leitman · 2019 [cited by examiner]
WO 0129058A1 · 2001 [cited by applicant]
WO 0183692A2 · 2001 [cited by applicant]
WO 0198584A2 · 2001 [cited by applicant]
WO 2012138475A1 · 2012 [cited by applicant]
WO WO2014121093A1 · 2014 [cited by examiner]
WO 2017040815A1 · 2017 [cited by applicant]
WO WO2017127750A1 · 2017 [cited by examiner]
WO 2021030149A1 · 2021 [cited by applicant]
WO 2021030153A2 · 2021 [cited by applicant]
WO 2021096868A1 · 2021 [cited by applicant]
WO 2021119489A1 · 2021 [cited by applicant]
WO 2022036068A1 · 2022 [cited by applicant]
Picard, Didier. “Posttranslational Regulation of Proteins by Fusions to Steroid-Binding Domains.” Methods in Enzymology, vol. 327, Elsevier, 2000, pp. 385-401. (Year: 2000). [cited by examiner]
Abraham, Robert T., and Arthur Weiss. “Jurkat T Cells and Development of the T-Cell Receptor Signalling Paradigm.” Nature Reviews Immunology, vol. 4, No. 4, Apr. 2004, pp. 301-308. (Year: 2004). [cited by examiner]
Alexander et al. (2017) “The Concise Guide to Pharmacology 2017/18: Nuclear Hormone Receptors”, British Journal of Pharmacology, 174(Suppl Suppl 1):S208-S224. [cited by applicant]
Altschul et al. (Oct. 5, 1990) “Basic Local Alignment Search Tool”, Journal of Molecular Biology, 215(3):403-410. [cited by applicant]
Altschul et al. (Sep. 1, 1997) “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs”, Nucleic Acids Research, 25(17):3389-3402. [cited by applicant]
Berge et al. (Dec. 1998) “Selective Expansion of a Peripheral Blood CD8+ Memory T Cell Subset Expressing Both Granzyme B and L-Selectin During Primary Viral Infection in Renal Allograft Recipients”, Transplantation Proc… [cited by applicant]
Bonifant et al. (Apr. 20, 2016) “Toxicity and Management in CAR T-Cell Therapy”, Molecular Therapy Oncolytics, 16011 (7 pages). [cited by applicant]
Brocard et al. (Sep. 1, 1998) “A Chimeric Cre Recombinase Inducible by Synthetic, but Not by Natural Ligands of the Glucocorticoid Receptor”, Nucleic Acids Research, 26(17):4086-4090. [cited by applicant]
Brocard et al. (Dec. 23, 1997) “Spatio-Temporally Controlled Site-Specific Somatic Mutagenesis in the Mouse”, Proceedings of the National Academy of Sciences of the United States of America, 94(26):14559-14563. [cited by applicant]
Chu et al. (Oct. 2008) “Novel Caspase-suicide Proteins for Tamoxifen-Inducible Apoptosis”, Genesis, 46(10):530-536. [cited by applicant]
Clackson et al. (Sep. 1, 1998) “Redesigning an FKBP-ligand Interface to Generate Chemical Dimerizers With Novel Specificity”, Proceedings of the National Academy of Sciences of the United States of America, 95(18):10437… [cited by applicant]
Danielian et al. (Feb. 1993) “Identification of Residues in the Estrogen Receptor That Confer Differential Sensitivity to Estrogen and Hydroxytamoxifen”, Molecular Endocrinology, 7(2):232-240. [cited by applicant]
Database Genbank. (Aug. 19, 2022) “BH3-interacting Domain Death Agonist Isoform 2 [ [cited by applicant]
Database Genbank. (Dec. 19, 2022) “BH3-interacting Domain Death Agonist Isoform 3 [ [cited by applicant]
Database Genbank. (Jul. 26, 2020) “ [cited by applicant]
Farzaneh et al. (Apr. 13, 2016) “Estrogen Receptor Ligands: A Review (2013-2015)”, Scientia Pharmaceutica, 84(3):409-427. [cited by applicant]
Feil et al. (Aug. 28, 1997) “Regulation of Cre Recombinase Activity by Mutated Estrogen Receptor Ligand-Binding Domains”, Biochemical and Biophysical Research Communications, 237(3):752-757. [cited by applicant]
Garland et al. (Jul. 30, 1999) “The Use of Teflon Cell Culture Bags to Expand Functionally Active CD8+ Cytotoxic T Lymphocytes”, Journal of Immunological Methods, 227(1-2):53-63. [cited by applicant]
Gross et al. (Jan. 8, 1999) “Caspase Cleaved BID Targets Mitochondria and is Required for Cytochrome C Release, While BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death”, Journal of Biological Chemi… [cited by applicant]
Haanen et al. (Nov. 1, 1999) “Selective Expansion of Cross-reactive CD8+ Memory T Cells by Viral Variants”, Journal of Experimental Medicine, 190(9):1319-1328. [cited by applicant]
Indra et al. (Nov. 15, 1999) “Temporally-Controlled Site-specific Mutagenesis in the Basal Layer of the Epidermis: Comparison of the Recombinase Activity of the Tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) Recombinases”… [cited by applicant]
Kaczmarczyk et al. (Aug. 1, 2003) “Induction of Cre Recombinase Activity Using Modified Androgen Receptor Ligand Binding Domains: a Sensitive Assay for Ligand-receptor Interactions”, Nucleic Acids Research, 31(15):e86 (… [cited by applicant]
Karlin et al. (Jun. 15, 1993) “Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences”, Proceedings of the National Academy of Sciences of the United States of America, 90(12):5873-5877. [cited by applicant]
Karlin et al. (Mar. 1990) “Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes”, Proceedings of the National Academy of Sciences of the United States of Ame… [cited by applicant]
Kellendonk et al. (Jan. 8, 1999) “Inducible Site-Specific Recombination in the Brain”, Journal of Molecular Biology, 285(1):175-182. [cited by applicant]
Kellendonk et al. (Apr. 1, 1996) “Regulation of Cre Recombinase Activity by the Synthetic Steroid RU 486”, Nucleic Acids Research, 24(8):1404-1411. [cited by applicant]
Kumar et al. (May 1999) “The Structure of the Nuclear Hormone Receptors”, Steroids, 64(5):310-319. [cited by applicant]
Li et al. (Aug. 21, 1998) “Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis”, Cell, 94(4):491-501. [cited by applicant]
Luo et al. (Aug. 21, 1998) “Bid, a Bcl2 Interacting Protein, Mediates Cytochrome C Release From Mitochondria in Response to Activation of Cell Surface Death Receptors”, Cell, 94(4):481-490. [cited by applicant]
Mangelsdorf et al. (Dec. 15, 1995) “The Nuclear Receptor Superfamily: The Second Decade”, Cell, 83(6):835-839. [cited by applicant]
Marsic et al. (Nov. 2014) “Vector Design Tour De Force: Integrating Combinatorial and Rational Approaches to Derive Novel Adeno-associated Virus Variants”, Molecular Therapy, 22(11):1900-1909. [cited by applicant]
Metzger et al. (Jul. 18, 1995) “Conditional Site-Specific Recombination in Mammalian Cells Using a Ligand-dependent Chimeric Cre Recombinase”, Proceedings of the National Academy of Sciences of the United States of Amer… [cited by applicant]
Miyazaki et al. (Feb. 14, 2012) “Destabilizing Domains Derived from the Human Estrogen Receptor”, Journal of the American Chemical Society, 134(9):3942-3945. [cited by applicant]
Muchmore et al. (May 23, 1996) “X-ray and NMR Structure of Human Bcl-xl, an Inhibitor of Programmed Cell Death”, Nature, 381(6580):335-341. [cited by applicant]
Petros et al. (Mar. 1, 2004) “Structural Biology of the Bcl-2 Family of Proteins”, Biochimica et Biophysica Acta, 1644(2-3):83-94. [cited by applicant]
Spencer et al. (Nov. 12, 1993) “Controlling Signal Transduction with Synthetic Ligands”, Science, 262(5136):1019-1024. [cited by applicant]
Stasi et al. (Nov. 3, 2011) “Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy”, The New England Journal of Medicine, 365(18):1673-1683. [cited by applicant]
Straathof et al. (Feb. 22, 2005) “An Inducible Caspase 9 Safety Switch for T-cell Therapy”, 105(11):4247-4254. [cited by applicant]
Takebayashi et al. (Sep. 1, 1996) “Hormone-induced Apoptosis by Fas-Nuclear Receptor Fusion Proteins: Novel Biological Tools for Controlling Apoptosis in Vivo”, Cancer Research, 56(18):4164-4170. [cited by applicant]
Tey, Siok-Keen. (Jun. 20, 2014) “Adoptive T-Cell Therapy: Adverse Events and Safety Switches”, Clinical & Translational Immunology, 3(6):e17 (7 pages). [cited by applicant]
Tey et al. (May 29, 2007) “Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells After Haploidentical Stem Cell Transplantation”, Biology of Blood and Marrow Transplantation, 13(8):913-924. [cited by applicant]
Wang et al. (Aug. 1994) “A Regulatory System for Use in Gene Transfer”, Proceedings of the National Academy of Sciences of the United States of America, 91:8180-8184. [cited by applicant]
Wootton et al. (Jun. 1993) “Statistics of Local Complexity in Amino Acid Sequences and Sequence Databases”, Computers & Chemistry, 17(2):149-163. [cited by applicant]
Zhou et al. (Nov. 2016) “Improving the Safety of T-Cell Therapies Using an Inducible Caspase-9 Gene”, Experimental Hematology, 44(11):1013-1019. [cited by applicant]